Cancer cells hijack cell death enzyme to regrow after treatment

-

 


The emergence of cancer drug resistance remains one of the most pressing problems in cancer care and there is a critical need to devise approaches to mitigate it. However, the molecular mechanisms driving treatment resistance are poorly understood, hindering efforts to devise new treatment strategies which prevent resistance. Now, researchers at the University of California San Diego have found a paradoxical new way in which cancer cells survive and regrow after targeted therapy: by hijacking an enzyme that is typically only switched on during cell death.

About one in six deaths worldwide are caused by cancer. Many of these deaths are ultimately attributable to acquired resistance following an initially positive treatment response. Cancer typically develops resistance to treatment through mutations over months to years, similar to how bacteria can evolve resistance to antibiotics over time. These mutations are difficult to treat with limited available drug combinations. However, the newly-discovered mechanism focuses on the earliest stages of resistance, which do not rely on genetic mutations, making it an attractive new target for future treatments.

"Most research on resistance focuses on genetic mutations," said first author August F. Williams, Ph.D., a postdoctoral fellow in the Hangauer lab at UC San Diego. "Our work shows that non‑genetic regrowth mechanisms can come into play much earlier, and they may be targetable with drugs. This approach could help patients stay in remission longer and reduce the risk of recurrence."

In the new study, the researchers found:In models of melanoma, lung and breast cancers, a subset of "persister" cells that survive treatment displayed chronic, low-level activation of a protein that dismantles DNA as a part of normal cell death, called DNA fragmentation factor B (DFFB).
This DFFB activation is at a level too low to kill the cells, but high enough to interfere with the cells' ability to respond to signals suppressing their growth.
Removing this protein keeps cancer persister cells dormant and prevents their regrowth during drug treatment.
DFFB is nonessential in normal cells, yet is required for regrowth cancer persister cells, making it a promising target for combination treatments to extend responses to targeted therapy.

#ResearchChemistry, #ChemicalInnovation, #Science, #ScienceResearch, #ScientificResearch, #ResearchAndDevelopment, #ChemistryEducation, #ChemistryExperiments, #ChemistryLab, #ChemistryStudents, #ChemistryStudy, #OrganicChemistry, #InorganicChemistry, #PhysicalChemistry, #AnalyticalChemistry, #Biochemistry, #MaterialsChemistry, #TheoreticalChemistry, #AppliedChemistry, #MedicinalChemistry

Comments

Post a Comment

Popular posts from this blog

Avoiding prostate cancer screening increases risk of death

-
Image
  Men who consistently avoid prostate cancer screening appointments face a disproportionately higher risk of dying from the disease, finds research identifying a new high-risk group. An analysis of data from across seven countries from the world's largest prostate cancer screening study, the European Randomized study of Screening for Prostate Cancer (ERSPC), is presented this weekend at the European Association of Urology (EAU) Congress in Madrid. Prostate cancer is the most common form of cancer in men in 112 countries, with prevalence expected to double by 2040. If introduced on a national scale, prostate cancer screening programmes that measure levels of prostate-specific antigen (PSA) in the blood have the potential to give men earlier access to treatment, a better chance of being cured. They can also prevent costly treatment associated with advanced prostate cancer. Long-term follow-up data from the ERSPC consistently report that PSA screening programmes can lead to a 20% re...
Read more

EchoBack CAR T-cells could be a game changer in cancer immunotherapy

-
Image
  Imagine a super-charged immune cell that can launch a focused attack on stubborn solid tumors - a smart fighter that destroys cancer cells for days without tiring. USC biomedical engineers have made this concept a reality, crafting what they have named the "EchoBack CAR T-cell," which could soon be a game changer in the field of cancer immunotherapy . The work, published in the scientific journal Cell, is a groundbreaking new approach that could overcome major obstacles in treating tumors that are not usually candidates for immunotherapy, while keeping healthy tissue safe. Chimeric antigen receptor (CAR) T-cell therapy is a promising field of cancer treatment that has shown great success in treating bloodborne cancers such as leukemia. It is a highly customized therapy in which cancer-fighting T-cells are drawn directly from the blood of a patient and given genetic modifications to enhance their ability to target and kill cancerous cells. The USC Alfred E. Mann Department ...
Read more

The Role of Analytical Chemistry in Industry and Manufacturing

-
Image
Industry and the manufacturing sector use multiple analytical chemical methods, whether for new product development, processing, or quality control. This article outlines the research to be presented at Pittcon on the advances being made in analytical chemistry and their application in industry and manufacturing. Spectroscopy is a valuable analytical tool for a wide range of sectors. Several talks will focus on Raman spectroscopy as a highly versatile analytical tool, which can be used in chemical processing from laboratory to manufacturing. Raman spectroscopy’s use in polymer science to measure and control chemical processes is a particular focus. The technique is becoming increasingly relevant as chemical manufacturing expands to include new developments such as batch reactions, microreactors, flow synthesis, and continuous processes. Pittcon will hear examples of using Raman spectroscopy to improve process efficiency and predict reaction end-times and physical properties of chemical...
Read more